Literature DB >> 32251120

Racial and Geographic Disparities in Endocrine Therapy Adherence Among Younger Breast Cancer Survivors.

Sue P Heiney1, Samantha Truman2, Oluwole A Babatunde2, Tisha M Felder1, Jan M Eberth3,2,4, Elizabeth Crouch4,5, Karen E Wickersham1, Swann Arp Adams1,3,2.   

Abstract

OBJECTIVES: African American (AA) women with breast cancer (BrCA) have higher mortality than any other race. Differential mortality has been attributed to nonadherence to endocrine therapy (ET). ET can lower the risk of dying by one third; yet 50% to 75% of all women are nonadherent to ET. Despite the wealth of research examining adherence to ET, understanding which groups of women at risk for poor adherence is not well established. The aim of this investigation was to describe ET adherence by race and geographic location among a cohort of younger BrCA survivors.
MATERIALS AND METHODS: Cancer registry records were linked to administrative data from Medicaid and a private insurance plan in South Carolina. Inclusion criteria included: European American (EA) or AA race, 3 years of continuous enrollment in the insurance plan after diagnosis, and BrCA diagnosis between 2002 and 2010. Adherence was measured by computing a medication possession ratio (MPR) based upon refill service dates and the number of pills dispensed. Adjusted least squared means were calculated by racial and geographic group using analysis of covariance methods.
RESULTS: The average MPR for EA women was significantly higher at 96% compared with 92% for AA women (P<0.01). After adjustment for years on hormone therapy, age, and number of pharmacies utilized, rural AA women had an average MPR of 90% compared with 95% for EA women (P<0.01).
CONCLUSIONS: AA women residing in rural areas demonstrate significantly lower adherence compared with their EA counterparts. Interventions are needed to improve adherence that may ameliorate AA mortality disparities.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32251120      PMCID: PMC7316591          DOI: 10.1097/COC.0000000000000696

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.787


  35 in total

1.  Person and place: the compounding effects of race/ethnicity and rurality on health.

Authors:  Janice C Probst; Charity G Moore; Saundra H Glover; Michael E Samuels
Journal:  Am J Public Health       Date:  2004-10       Impact factor: 9.308

Review 2.  Methods for evaluation of medication adherence and persistence using automated databases.

Authors:  Susan E Andrade; Kristijan H Kahler; Feride Frech; K Arnold Chan
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-08       Impact factor: 2.890

3.  Patient-reported Adherence to Adjuvant Aromatase Inhibitor Therapy Using the Morisky Medication Adherence Scale: An Evaluation of Predictors.

Authors:  Susan B Kesmodel; Olga G Goloubeva; Paula Y Rosenblatt; Brian Heiss; Emily C Bellavance; Saranya Chumsri; Ting Bao; Jennifer Thompson; Ginah Nightingale; Nancy S Tait; Elizabeth M Nichols; Steve J Feigenberg; Katherine H Tkaczuk
Journal:  Am J Clin Oncol       Date:  2018-05       Impact factor: 2.339

4.  Endocrine therapy initiation among Medicaid-insured breast cancer survivors with hormone receptor-positive tumors.

Authors:  Stephanie Brooke Wheeler; Racquel Elizabeth Kohler; Katherine Elizabeth Reeder-Hayes; Ravi K Goyal; Kristen Hassmiller Lich; Alexis Moore; Timothy W Smith; Cathy L Melvin; Hyman Bernard Muss
Journal:  J Cancer Surviv       Date:  2014-05-28       Impact factor: 4.442

5.  Racial and geographic disparities in adherence and discontinuation to adjuvant endocrine therapy in Texas Medicaid-insured patients with breast cancer.

Authors:  Albert J Farias; Wen-Hsing Wu; Xianglin L Du
Journal:  Med Oncol       Date:  2018-06-20       Impact factor: 3.064

6.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Authors: 
Journal:  Lancet       Date:  2005 May 14-20       Impact factor: 79.321

7.  Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer.

Authors:  Dawn L Hershman; Theresa Shao; Lawrence H Kushi; Donna Buono; Wei Yann Tsai; Louis Fehrenbacher; Marilyn Kwan; Scarlett Lin Gomez; Alfred I Neugut
Journal:  Breast Cancer Res Treat       Date:  2010-08-28       Impact factor: 4.872

8.  Persistence on prostaglandin ocular hypotensive therapy: an assessment using medication possession and days covered on therapy.

Authors:  Gregory Reardon; Gail F Schwartz; Sameer Kotak
Journal:  BMC Ophthalmol       Date:  2010-03-02       Impact factor: 2.209

9.  Adjuvant hormonal therapy use among insured, low-income women with breast cancer.

Authors:  Gretchen Kimmick; Roger Anderson; Fabian Camacho; Monali Bhosle; Wenke Hwang; Rajesh Balkrishnan
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

Review 10.  Medication compliance and persistence: terminology and definitions.

Authors:  Joyce A Cramer; Anuja Roy; Anita Burrell; Carol J Fairchild; Mahesh J Fuldeore; Daniel A Ollendorf; Peter K Wong
Journal:  Value Health       Date:  2008 Jan-Feb       Impact factor: 5.725

View more
  9 in total

1.  Sociodemographic disparities in molecular testing for breast cancer.

Authors:  Whitney E Zahnd; Radhika Ranganathan; Swann Arp Adams; Oluwole A Babatunde
Journal:  Cancer Causes Control       Date:  2022-04-27       Impact factor: 2.506

2.  Cost-Related Medication Nonadherence and Patient Cost Responsibility for Rural and Urban Cancer Survivors.

Authors:  Courtney P Williams; Amy Davidoff; Michael T Halpern; Michelle Mollica; Kathleen Castro; Benjamin Allaire; Janet S de Moor
Journal:  JCO Oncol Pract       Date:  2022-08

3.  Accuracy of tumor registry versus pharmacy dispensings for breast cancer adjuvant endocrine therapy.

Authors:  Cameron B Haas; Erin J Aiello Bowles; Janie M Lee; Jennifer Specht; Diana S M Buist
Journal:  Cancer Causes Control       Date:  2022-07-07       Impact factor: 2.532

4.  Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001-2016.

Authors:  Erin J Aiello Bowles; Cody Ramin; Diana S M Buist; Heather Spencer Feigelson; Sheila Weinmann; Lene H S Veiga; Clara Bodelon; Rochelle E Curtis; Jacqueline B Vo; Amy Berrington de Gonzalez; Gretchen L Gierach
Journal:  Breast Cancer Res Treat       Date:  2022-03-11       Impact factor: 4.872

Review 5.  The Intersection of Rural Residence and Minority Race/Ethnicity in Cancer Disparities in the United States.

Authors:  Whitney E Zahnd; Cathryn Murphy; Marie Knoll; Gabriel A Benavidez; Kelsey R Day; Radhika Ranganathan; Parthenia Luke; Anja Zgodic; Kewei Shi; Melinda A Merrell; Elizabeth L Crouch; Heather M Brandt; Jan M Eberth
Journal:  Int J Environ Res Public Health       Date:  2021-02-03       Impact factor: 3.390

6.  Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States.

Authors:  Jessica E Hawley; Tianyi Sun; David D Chism; Narjust Duma; Julie C Fu; Na Tosha N Gatson; Sanjay Mishra; Ryan H Nguyen; Sonya A Reid; Oscar K Serrano; Sunny R K Singh; Neeta K Venepalli; Ziad Bakouny; Babar Bashir; Mehmet A Bilen; Paolo F Caimi; Toni K Choueiri; Scott J Dawsey; Leslie A Fecher; Daniel B Flora; Christopher R Friese; Michael J Glover; Cyndi J Gonzalez; Sharad Goyal; Thorvardur R Halfdanarson; Dawn L Hershman; Hina Khan; Chris Labaki; Mark A Lewis; Rana R McKay; Ian Messing; Nathan A Pennell; Matthew Puc; Deepak Ravindranathan; Terence D Rhodes; Andrea V Rivera; John Roller; Gary K Schwartz; Sumit A Shah; Justin A Shaya; Mitrianna Streckfuss; Michael A Thompson; Elizabeth M Wulff-Burchfield; Zhuoer Xie; Peter Paul Yu; Jeremy L Warner; Dimpy P Shah; Benjamin French; Clara Hwang
Journal:  JAMA Netw Open       Date:  2022-01-04

7.  The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005).

Authors:  Fangfang Duan; Muyi Zhong; Yuyu Ma; Chenge Song; Lehong Zhang; Ying Lin; Zhiyong Wu; Yuanqi Zhang; Jiajia Huang; Fei Xu; Yanxia Shi; Shusen Wang; Zhongyu Yuan; Wen Xia; Xiwen Bi
Journal:  BMC Cancer       Date:  2022-03-15       Impact factor: 4.430

8.  Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer.

Authors:  Xin Hu; Mark S Walker; Edward Stepanski; Cameron M Kaplan; Michelle Y Martin; Gregory A Vidal; Lee S Schwartzberg; Ilana Graetz
Journal:  JAMA Netw Open       Date:  2022-08-01

9.  Adherence to Adjuvant Hormonal Therapy and Associated Factors Among Women with Breast Cancer Attending the Tikur Anbessa Specialized Hospital, Addis Ababa Ethiopia, 2019: A Cross-sectional Study.

Authors:  Zerko Wako; Daniel Mengistu; Negalign Getahun Dinegde; Tseganesh Asefa; Mulugeta Wassie
Journal:  Breast Cancer (Dove Med Press)       Date:  2021-06-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.